Search results
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74.
Apr 18, 2022 · Our combination of focused innovation and commercial scale brings differentiated products to market that benefit patients, customers and health care providers. AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
May 7, 2024 · Our Global Product Protection Team constantly analyzes our global supply chain, seeking out weak points and identifying opportunities to reduce the possibility of product interference. Download our Exclusive Sourcing Agreement. View names and safety data sheets for our products.
May 7, 2024 · ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways with demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone. AbbVie and Alpine have entered into an exclusive worldwide option and license agreement for ALPN-101.
At AbbVie, we believe everyone should have access to quality and affordable medicines if and when they need them. We help patients get the medicines they need by offering various access and support programs.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma ...
AbbVie is a global biopharmaceutical company with focus and capabilities to address some of the world's greatest health challenges. AbbVie discovers, develops, and commercializes advanced therapies that have an impact on people's lives.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health...
May 13, 2024 · Under terms of the agreement, AbbVie and Gilgamesh have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders. Upon exercise of the option, AbbVie will lead development and commercialization activities.
